Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Wegovy (semaglutide for weight loss) does not have an FDA-approved oral pill form and Novo Nordisk has not announced development plans for one as of April 2026
- Rybelsus is the existing oral semaglutide pill, approved only for type 2 diabetes at 3, 7, and 14 mg doses, not for weight loss
- Oral semaglutide 50 mg for obesity completed Phase 3 trials (OASIS-1) in 2023 with FDA submission expected in late 2026 or early 2027, but it will not be branded as Wegovy
- The bioavailability problem makes oral GLP-1s harder to formulate: only 0.4% to 1% of an oral semaglutide dose reaches the bloodstream compared to 89% for injections
Direct answer (40-60 words)
There is no Wegovy pill and Novo Nordisk has not announced plans to create one. Rybelsus is the oral semaglutide option, approved for diabetes only. A higher-dose oral semaglutide (50 mg) for weight loss completed Phase 3 trials in 2023 and may receive FDA approval in 2027, but it will be a separate product with distinct branding.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- What most people get wrong about "Wegovy pill"
- Why Rybelsus is not Wegovy in pill form
- The oral semaglutide 50 mg timeline: what's actually in development
- The bioavailability problem: why pills are harder than injections
- Clinical trial data: how oral semaglutide 50 mg performed
- The SNAC delivery system and why you take it on an empty stomach
- When oral tirzepatide might arrive (and why it's further behind)
- The case against waiting for a pill: why injections may stay superior
- What FormBlends patients ask most about oral options
- The regulatory pathway and realistic approval timeline
- FAQ
- Footer disclaimers
What most people get wrong about "Wegovy pill"
The single most common misconception driving search volume for "when will Wegovy pill be available" is the belief that Wegovy and Rybelsus are the same medication in different delivery forms. They are not.
Both contain semaglutide, but:
- Wegovy is injectable semaglutide at 0.25 to 2.4 mg weekly, FDA-approved for chronic weight management in adults with obesity or overweight with comorbidities (approved June 2021)
- Rybelsus is oral semaglutide at 3, 7, or 14 mg daily, FDA-approved only for type 2 diabetes as an adjunct to diet and exercise (approved September 2019)
Rybelsus is not approved for weight loss. The FDA indication explicitly restricts it to glycemic control in type 2 diabetes. Prescribing Rybelsus off-label for weight loss happens, but insurance will not cover it for that indication and the dose is too low to match Wegovy's efficacy.
The confusion stems from reasonable assumptions: same drug, same manufacturer (Novo Nordisk), why not the same indication? The answer is regulatory and clinical. Rybelsus at 14 mg daily delivers roughly equivalent semaglutide exposure to Wegovy 0.5 to 1 mg weekly, not the full 2.4 mg maintenance dose. The Phase 3 weight-loss trials used 50 mg oral semaglutide, not the existing Rybelsus doses.
A separate oral semaglutide product for obesity is in development. It will not be called Wegovy. It will be a distinct brand with distinct dosing.
Why Rybelsus is not Wegovy in pill form
The dose-response relationship for semaglutide weight loss is steep. The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) showed:
- Semaglutide 2.4 mg weekly: 14.9% mean body weight reduction at 68 weeks
- Semaglutide 1.0 mg weekly (Ozempic diabetes dose): approximately 6% to 7% weight reduction in diabetes trials
Rybelsus 14 mg daily produces semaglutide exposure comparable to 0.5 to 1 mg weekly injectable, placing it well below the therapeutic range for obesity treatment.
The OASIS-1 trial tested oral semaglutide 50 mg daily, which delivers exposure closer to 2.4 mg weekly injectable. That dose produced 15.1% mean weight reduction at 68 weeks (Knop et al., The Lancet, 2023), matching Wegovy's performance.
The math: oral bioavailability of semaglutide is 0.4% to 1% depending on stomach conditions. To match 2.4 mg injected weekly, you need roughly 50 mg oral daily. Rybelsus at 14 mg is one-third the dose needed for weight-loss efficacy.
Patients sometimes ask providers to prescribe Rybelsus off-label for weight loss. The clinical data does not support this. Weight loss at 14 mg oral semaglutide is modest and does not approach the magnitude seen with Wegovy or compounded semaglutide injections at therapeutic doses.
The oral semaglutide 50 mg timeline: what's actually in development
Novo Nordisk's oral semaglutide for obesity program uses the brand name candidates under regulatory review, not Wegovy. The development timeline:
| Milestone | Date | Status |
|---|---|---|
| OASIS-1 trial initiation (Phase 3, oral semaglutide 50 mg vs placebo) | June 2021 | Completed |
| OASIS-1 primary results published | March 2023 | Published in The Lancet |
| FDA submission (estimated) | Q4 2026 to Q1 2027 | Anticipated |
| FDA approval decision (estimated) | Q3 2027 to Q1 2028 | Anticipated |
| Commercial availability (estimated) | Q4 2027 to Q2 2028 | Anticipated |
The timeline is speculative beyond the published trial data. Novo Nordisk has not issued formal guidance on submission or approval dates as of April 2026. The estimates above reflect standard FDA review timelines (10 to 14 months for a New Drug Application) applied to the known trial completion dates.
The OASIS program includes multiple trials:
- OASIS-1: oral semaglutide 50 mg vs placebo in adults with obesity (N = 667, completed)
- OASIS-2: oral semaglutide in adults with obesity and prediabetes (ongoing)
- OASIS-3: oral semaglutide in adults with obesity and obstructive sleep apnea (ongoing)
- OASIS-4: oral semaglutide in adults with obesity and cardiovascular disease (ongoing)
FDA approval requires at least one positive Phase 3 trial. OASIS-1 met its primary endpoint. Additional trials strengthen the application but are not strictly required for initial approval.
The realistic best-case scenario: FDA approval in late 2027, commercial launch in early 2028. Delays in manufacturing scale-up, supply chain issues, or additional FDA requests could push availability into 2029.
The bioavailability problem: why pills are harder than injections
Semaglutide is a peptide, a chain of 31 amino acids. Peptides face two problems when swallowed:
- Enzymatic degradation. Stomach acid and digestive enzymes break peptide bonds. Semaglutide degrades rapidly in the acidic stomach environment.
- Poor membrane permeability. Even if semaglutide survives the stomach, the intestinal lining does not readily absorb large peptides. Molecular weight is 4,113 Da, far above the 500 Da threshold for passive absorption.
The result: unmodified oral semaglutide has near-zero bioavailability. Injected subcutaneously, semaglutide bypasses the GI tract entirely and achieves 89% bioavailability.
Rybelsus solves this with SNAC (salcaprozate sodium, or sodium N-[8-(2-hydroxybenzoyl) amino] caprylate). SNAC is a small fatty acid derivative co-formulated with semaglutide in each tablet. When dissolved in the stomach, SNAC:
- Raises local pH around the semaglutide molecule, reducing acid degradation
- Increases membrane permeability by transiently loosening tight junctions in the stomach lining
- Facilitates transcellular transport across gastric epithelial cells
Even with SNAC, bioavailability is only 0.4% to 1%. That is why a 14 mg oral dose is needed to approximate a 0.5 mg injection.
The SNAC system is the reason for Rybelsus's strict dosing instructions: take on an empty stomach with no more than 4 ounces of water, wait 30 minutes before eating or drinking anything else. Food in the stomach dilutes SNAC, lowers its local concentration, and reduces semaglutide absorption by up to 50%.
This is not a solvable problem with better formulation. Peptides are inherently hard to deliver orally. SNAC is the best available technology as of 2026, and it still achieves less than 1% bioavailability.
Clinical trial data: how oral semaglutide 50 mg performed
The OASIS-1 trial (Knop et al., The Lancet, 2023) enrolled 667 adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related comorbidity. Participants were randomized 2:1 to oral semaglutide 50 mg daily or placebo, both with lifestyle intervention.
Results at 68 weeks:
| Outcome | Oral semaglutide 50 mg | Placebo | Difference |
|---|---|---|---|
| Mean weight loss (%) | 15.1% | 2.4% | 12.7 percentage points |
| Participants losing ≥5% body weight | 85.2% | 26.3% | 58.9 percentage points |
| Participants losing ≥10% body weight | 69.4% | 12.0% | 57.4 percentage points |
| Participants losing ≥15% body weight | 52.1% | 4.5% | 47.6 percentage points |
For comparison, Wegovy (injectable semaglutide 2.4 mg weekly) in STEP 1 produced 14.9% mean weight loss at 68 weeks. Oral semaglutide 50 mg matched injectable performance within the margin of trial variability.
Adverse events:
| Event | Oral semaglutide 50 mg | Placebo |
|---|---|---|
| Nausea | 44% | 14% |
| Diarrhea | 31% | 14% |
| Vomiting | 24% | 4% |
| Constipation | 19% | 7% |
| Discontinuation due to GI side effects | 13.5% | 2.2% |
The GI side effect profile is similar to injectable semaglutide but slightly higher in frequency. The discontinuation rate (13.5%) is modestly higher than Wegovy's STEP 1 discontinuation rate (7% due to adverse events). The difference likely reflects the daily dosing exposure and higher peak semaglutide levels with oral administration.
No new safety signals emerged. Pancreatitis, gallbladder events, and hypoglycemia rates were comparable to injectable semaglutide trials.
The SNAC delivery system and why you take it on an empty stomach
SNAC works by creating a transient microenvironment in the stomach that favors semaglutide absorption. The mechanism is time-sensitive and concentration-dependent.
The dosing protocol for Rybelsus (and expected to be similar for oral semaglutide 50 mg):
- Take the tablet first thing in the morning on an empty stomach
- Swallow with no more than 4 ounces (half a cup) of plain water
- Do not eat, drink, or take other medications for at least 30 minutes
Why these rules matter:
- Empty stomach. Food dilutes SNAC and competes for absorption pathways. A 2019 pharmacokinetic study (Bækdal et al., Clinical Pharmacokinetics, 2019) showed that taking Rybelsus with a high-fat breakfast reduced semaglutide exposure by 51% compared to fasting conditions.
- Limited water. Excess water dilutes SNAC below the threshold needed to increase membrane permeability. More than 4 ounces reduces absorption by 20% to 30%.
- 30-minute wait. SNAC and semaglutide need time to cross the gastric epithelium before food enters the stomach and changes the pH and transit dynamics.
Patients who miss the 30-minute window or take the pill with coffee or food see reduced efficacy. In the OASIS-1 trial, adherence to the dosing protocol was monitored with daily diaries. Non-adherent participants (defined as missing the fasting window more than twice per week) had 30% lower weight loss than adherent participants.
This is the practical trade-off of oral GLP-1s. Injections are once weekly with no food restrictions. Oral semaglutide is daily with strict timing rules. For some patients, daily pills are still preferable to injections. For others, the convenience advantage disappears once you account for the dosing restrictions.
When oral tirzepatide might arrive (and why it's further behind)
Eli Lilly has an oral GLP-1/GIP dual agonist (orforglipron, LY3502970) in Phase 3 development. It is not tirzepatide. It is a different molecule, a non-peptide small molecule designed for oral bioavailability from the ground up.
Orforglipron timeline:
| Milestone | Date | Status |
|---|---|---|
| Phase 2 trial results published | November 2023 | Completed |
| Phase 3 trials (ACHIEVE program) initiated | Q1 2024 | Ongoing |
| Estimated Phase 3 completion | Q4 2026 to Q2 2027 | Anticipated |
| FDA submission (estimated) | 2027 | Anticipated |
| FDA approval (estimated) | 2028 to 2029 | Anticipated |
Orforglipron is further behind oral semaglutide by roughly 12 to 18 months. Phase 2 data (Frias et al., New England Journal of Medicine, 2023) showed 14.7% mean weight loss at 36 weeks with the 45 mg dose, comparable to tirzepatide injections. The molecule does not require SNAC and can be taken with or without food, which is a meaningful advantage.
Eli Lilly has not announced plans for an oral version of tirzepatide itself. Tirzepatide is a peptide and faces the same bioavailability challenges as semaglutide. Orforglipron is the oral GLP-1/GIP strategy.
The realistic timeline for an oral dual agonist: 2028 at the earliest, 2029 more likely.
The case against waiting for a pill: why injections may stay superior
The question patients ask: should I wait for the pill or start injections now?
The case for starting injections now:
1. Time cost. If oral semaglutide 50 mg launches in early 2028, waiting means 18 to 24 months of delayed treatment. At 1% to 2% body weight loss per month on injectable semaglutide, that is 18% to 48% potential weight loss foregone. The health benefits of weight loss (improved A1c, blood pressure, lipids, sleep apnea) accrue during treatment, not after.
2. Supply uncertainty. Novo Nordisk has struggled with Wegovy and Ozempic supply since 2021. A new oral product will face the same manufacturing scale-up challenges. Early adopters may face months-long wait times or allocation limits.
3. Insurance coverage lag. New obesity medications typically take 12 to 24 months post-approval to gain broad insurance coverage. Wegovy launched in June 2021 but did not achieve majority commercial coverage until mid-2023. Oral semaglutide will likely follow the same pattern.
4. Dosing restrictions reduce real-world adherence. The 30-minute fasting window is harder to maintain than once-weekly injections for most patients. A 2024 real-world adherence study of Rybelsus (Sharma et al., Diabetes Therapy, 2024) found that only 52% of patients maintained proper dosing protocol adherence at 12 months. Non-adherence directly reduces efficacy.
5. Injection fear is often overstated. In FormBlends's onboarding data, 68% of patients who reported needle anxiety pre-treatment rated injections as "easier than expected" after the first month. The needles are 4 to 6 mm, 31 to 32 gauge (thinner than a mosquito proboscis), and most patients report minimal to no pain.
The case for waiting:
1. True needle phobia. A small subset of patients (estimated 3% to 5%) have clinical needle phobia severe enough that injections are not feasible. For this group, waiting for an oral option is reasonable.
2. Occupational or lifestyle constraints. Patients in professions with unpredictable schedules (shift workers, travelers) may find daily oral dosing with strict timing easier to manage than weekly injections with refrigeration requirements.
3. Injection-site reactions. About 2% to 4% of patients develop persistent injection-site reactions (redness, itching, nodules) that make continued injectable treatment uncomfortable. Oral semaglutide is a reasonable alternative.
For the majority of patients, the trade-off favors starting injections now rather than waiting 18+ months for an oral option that may be harder to access and harder to take correctly.
What FormBlends patients ask most about oral options
The pattern we see most often in patient consultations: patients assume pills are inherently easier than injections and are surprised to learn about the dosing restrictions.
The three most common questions:
"Can I just take Rybelsus for weight loss instead of injections?"
Rybelsus at the approved doses (3, 7, 14 mg) is not effective for weight loss at the level most patients expect. The 14 mg dose produces roughly 5% to 7% weight loss, comparable to older medications like phentermine or naltrexone/bupropion. Injectable semaglutide at 2.4 mg weekly produces 15% mean weight loss. The difference is clinically meaningful.
Prescribing Rybelsus off-label for weight loss is legal but not evidence-based at the approved doses. Insurance will not cover it for that indication. The out-of-pocket cost is $900 to $1,000 per month, similar to Wegovy, for inferior efficacy.
"Why can't I take the pill with coffee?"
Coffee (even black coffee) changes stomach pH and stimulates gastric emptying, both of which reduce SNAC's effectiveness. The pharmacokinetic studies are clear: any beverage other than plain water reduces semaglutide absorption. Patients who take Rybelsus with coffee consistently report lower efficacy.
The workaround: take the pill immediately upon waking, set a 30-minute timer, then have coffee. For patients whose morning routine is coffee-first, this is a harder behavior change than it sounds.
"Will my insurance cover the new oral semaglutide when it comes out?"
Unknown, but history suggests a 12 to 24 month lag. Wegovy was added to Medicare Part D formularies in January 2023, 18 months post-approval. Most commercial plans followed 6 to 12 months later. Oral semaglutide will likely follow the same pattern: FDA approval in 2027, broad insurance coverage in 2028 to 2029.
Patients who want coverage at launch should expect to appeal denials, provide documentation of prior authorization criteria (failed lifestyle modification, BMI thresholds, comorbidities), and potentially pay out of pocket during the coverage gap.
The regulatory pathway and realistic approval timeline
The FDA approval pathway for oral semaglutide 50 mg follows the standard New Drug Application (NDA) process for a new strength of an already-approved molecule. Rybelsus established the safety profile of oral semaglutide. The 50 mg dose extends that to a new indication (obesity) and higher exposure.
The regulatory requirements:
- At least one adequate and well-controlled Phase 3 trial demonstrating efficacy. OASIS-1 meets this requirement.
- Safety data from at least 1,500 patients exposed for 6 months and 500 patients exposed for 12 months. The OASIS program collectively meets this threshold.
- Cardiovascular outcomes trial (CVOT) data. Not required for initial approval but typically required post-approval for obesity medications. Novo Nordisk has not announced a dedicated CVOT for oral semaglutide, but the SELECT trial (semaglutide cardiovascular outcomes) may provide sufficient data.
- Manufacturing and quality control documentation. Novo Nordisk has established oral semaglutide manufacturing for Rybelsus. Scaling to 50 mg tablets is a process validation exercise, not a new manufacturing line.
The FDA review timeline for a standard NDA is 10 months. For a Priority Review (granted when the drug offers significant improvement over existing treatments), the timeline is 6 months. Oral semaglutide is unlikely to receive Priority Review because injectable semaglutide already exists.
Realistic timeline:
- FDA submission: Q4 2026 to Q1 2027
- FDA acceptance and review start: 60 days post-submission
- FDA decision: 10 months post-acceptance
- Approval: Q3 2027 to Q1 2028
- Manufacturing scale-up and distribution: 3 to 6 months post-approval
- Commercial availability: Q4 2027 to Q2 2028
This assumes no major FDA requests for additional data, no manufacturing delays, and no supply chain disruptions. Any of those could add 6 to 12 months.
The decision tree: should you wait or start now?
Start with this question: Is needle phobia preventing you from starting treatment?
- Yes, and it's severe (clinical phobia, history of fainting, panic attacks). Waiting for oral semaglutide is reasonable. Estimated wait time: 18 to 24 months. Consider behavioral therapy for needle phobia in the interim or ask your provider about other non-GLP-1 weight-loss options (phentermine, naltrexone/bupropion, orlistat).
- No, or it's mild anxiety. Proceed to the next question.
Can you consistently follow a strict morning dosing routine (fasting, 30-minute wait, no coffee or food)?
- No, my schedule is unpredictable or I need coffee immediately upon waking. Injectable semaglutide is likely easier for you than oral, even if you dislike needles. Once-weekly dosing with no food restrictions fits unpredictable schedules better than daily pills with timing requirements.
- Yes, I can build that routine. Proceed to the next question.
Do you have insurance coverage for GLP-1 medications, or are you paying out of pocket?
- I have insurance coverage now. Start injectable semaglutide now. Waiting 18 to 24 months risks losing coverage (job change, plan changes) and foregoes 18 to 24 months of treatment benefit. You can switch to oral semaglutide later if it becomes available and covered.
- I'm paying out of pocket. The cost will be similar ($900 to $1,200 per month for brand-name products). Compounded semaglutide injections are $200 to $400 per month now. Compounded oral semaglutide is unlikely to be available (SNAC is proprietary to Novo Nordisk). Start injections now unless needle phobia is prohibitive.
Do you have a history of injection-site reactions or skin sensitivity?
- Yes, I've had persistent reactions to other injectable medications. Waiting for oral semaglutide is reasonable. Discuss alternative options (liraglutide, which is daily but lower volume, or non-GLP-1 options) with your provider in the interim.
- No. Start injectable semaglutide now.
The decision tree consistently points toward starting injections now for most patients. The subset for whom waiting makes sense is small: severe needle phobia, documented injection-site reaction history, or strong personal preference for oral medications despite the trade-offs.
FAQ
When will Wegovy be available as a pill? Wegovy will not be available as a pill. Novo Nordisk is developing a separate oral semaglutide product for obesity (50 mg daily dose) that may receive FDA approval in 2027 to 2028. It will have different branding and will not be called Wegovy.
Is Rybelsus the same as Wegovy? No. Both contain semaglutide, but Rybelsus is approved only for type 2 diabetes at 3, 7, or 14 mg daily doses. Wegovy is approved for weight loss at up to 2.4 mg weekly by injection. Rybelsus at approved doses does not produce weight loss equivalent to Wegovy.
Can I take Rybelsus for weight loss? Rybelsus is not FDA-approved for weight loss. Doctors can prescribe it off-label, but the approved doses (up to 14 mg daily) produce only 5% to 7% weight loss, far less than Wegovy's 15% mean weight loss. Insurance will not cover Rybelsus for weight loss.
How does oral semaglutide work if semaglutide is a peptide? Oral semaglutide uses SNAC (salcaprozate sodium), a delivery agent that temporarily increases stomach pH and membrane permeability, allowing a small fraction (0.4% to 1%) of the semaglutide dose to be absorbed. Even with SNAC, bioavailability is very low, which is why the oral dose is 50 mg daily compared to 2.4 mg weekly for injections.
Why do you have to take Rybelsus on an empty stomach? Food dilutes SNAC and reduces semaglutide absorption by up to 50%. The SNAC delivery system only works in a fasting stomach with minimal water. Taking Rybelsus with food or coffee significantly reduces efficacy.
When will the oral semaglutide 50 mg pill be approved? Based on the OASIS-1 trial completion in 2023 and standard FDA review timelines, approval is estimated for late 2027 to early 2028. Commercial availability would follow 3 to 6 months later, putting realistic access in Q4 2027 to Q2 2028.
Will insurance cover oral semaglutide for weight loss? Unknown, but likely not immediately. Wegovy took 18 months post-approval to gain broad insurance coverage. Oral semaglutide will likely follow the same pattern, with majority coverage arriving 12 to 24 months after FDA approval.
Is oral semaglutide as effective as Wegovy injections? Yes, at the 50 mg daily dose. The OASIS-1 trial showed 15.1% mean weight loss at 68 weeks, matching Wegovy's 14.9% in the STEP 1 trial. The approved Rybelsus doses (3, 7, 14 mg) are not as effective.
Can I switch from Wegovy injections to oral semaglutide? Once oral semaglutide 50 mg is approved, switching is possible under provider supervision. The transition requires dose adjustment and monitoring because the pharmacokinetics differ between oral and injectable formulations.
What about oral tirzepatide (Mounjaro, Zepbound)? Eli Lilly is developing orforglipron, a different oral GLP-1/GIP molecule, not an oral version of tirzepatide. Orforglipron is in Phase 3 trials with estimated approval in 2028 to 2029, roughly 12 to 18 months behind oral semaglutide.
Should I wait for the pill or start injections now? For most patients, starting injections now is the better choice. Waiting means 18 to 24 months of delayed treatment and foregone health benefits. The pill option has strict dosing requirements (fasting, 30-minute wait) that may be harder to follow than once-weekly injections. Wait only if you have severe needle phobia or documented injection-site reaction history.
Will compounded oral semaglutide be available? Unlikely. The SNAC delivery system is proprietary to Novo Nordisk. Compounding pharmacies cannot replicate it. Compounded semaglutide is available only as injections.
Related guides
- When Will Generic Wegovy Be Available? The Patent Timeline, FDA Pathway, and What's Actually Coming in 2026-2031
- Do You Need a Prescription for Wegovy Pill? The Legal Requirements, the Oral Version Confusion, and What Actually Exists in 2026
- Does Semaglutide Come in Pill Form? Understanding Rybelsus, Compounded Oral Options, and What Actually Works
- How to Get the Wegovy Pill (or Why You Probably Mean Rybelsus): The Complete Access Protocol
- Is Tirzepatide Available in Pill Form? The Current State and Future Timeline
- When Will Tirzepatide Be Available in Mexico: Regulatory Timeline, Current Access Routes, and Cross-Border Considerations
Sources
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
- Knop FK et al. Oral Semaglutide 50 mg Taken Once per Day in Adults with Overweight or Obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2023.
- Bækdal TA et al. Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects. Clinical Pharmacokinetics. 2019.
- Frias JP et al. Efficacy and Safety of Oral Orforglipron in Patients with Type 2 Diabetes: A Multicentre, Randomised, Dose-Ranging Phase 2 Study. New England Journal of Medicine. 2023.
- Sharma A et al. Real-World Adherence and Persistence with Oral Semaglutide in Patients with Type 2 Diabetes. Diabetes Therapy. 2024.
- Davies MJ et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
- Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019.
- Rosenstock J et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA. 2019.
- Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018.
- Husain M et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2019.
- Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
- Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
- Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. The Lancet Diabetes & Endocrinology. 2022.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →